Abstract

Monogenic diabetes (MD) includes several forms of hyperglycemia caused by mutations in genes capable of controlling glucose homeostasis. Although MD explains 0.5-5.0% of non-autoimmune diabetes, it remains mostly overlooked. This is unfortunate, given that most of the genes involved in MD influence the monitoring and/or therapy of carrier patients, thus representing an excellent example of “precision medicine” implemented in real-life clinical practice. This review provides a practical update to help identify patients who merit genetic testing for MD and how to best clinically manage carrier patients.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call